Registry of patients with pulmonary hypertension receiving targeted therapy
CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy
This study is collecting information from over 5,000 patients in China with pulmonary hypertension who are using targeted therapies to see how well these treatments work and how the disease progresses over three years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Chinese Pulmonary Vascular Disease Research Group Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06135909 on ClinicalTrials.gov |
What this trial studies
The CHASE Registry aims to collect and analyze clinical characteristics and treatment strategies of patients with pulmonary hypertension in China who are receiving targeted therapies. This multicenter, prospective observational study will enroll at least 5000 patients, who will be followed for three years with assessments every six months. The study focuses on real-world data to understand disease progression, treatment outcomes, and the effectiveness of targeted drugs in managing pulmonary hypertension.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18 to 85 with a clinical diagnosis of pulmonary hypertension who are currently using or planning to use targeted therapies.
Not a fit: Patients with a history of mental illness, drug addiction, or those with a life expectancy of less than six months due to other diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management and treatment outcomes of pulmonary hypertension, potentially improving patient care.
How similar studies have performed: Other studies focusing on real-world data collection in pulmonary hypertension have shown promise, indicating that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sign informed consent; * Between the ages of 18 and 85; * Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists). Exclusion Criteria: * Have a history of mental illness or drug or poison addiction, and can not sign informed consent or can not cooperate with the experimental study; * Patients with malignant tumor and other diseases and life expectancy of less than half a year; * Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension
Where this trial is running
Beijing
- Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Zhihong Liu, M.D., Ph.D — Chinese Academy of Medical Sciences, Fuwai Hospital
- Study coordinator: Zhihong Liu, M.D., Ph.D
- Email: zhihongliufuwai@163.com
- Phone: 8601088396816
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.